53. Sjogren syndrome Clinical trials / Disease details


Clinical trials : 305 Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100052314
2021-11-012021-10-24Effect of triamcinolone acetonide for parotid gland lavage on the salivary secretion of patients with Sjogren's syndromeEffect of triamcinolone acetonide irrigation through parotid duct for parotid gland salivary secretion of patients with Sjogren's syndrome Sjogren syndromeExperimental Group:Perfusing parotid gland with triamcinolone acetonide injection through parotid duct;Control Group:The parotid gland was perfused with normal saline through parotid duct;Affiliated Stomatological Hospital of Nanjing Medical UniversityNULLPending2080BothExperimental Group:27;Control Group:27;Phase 4China
2NCT02112019
(ClinicalTrials.gov)
June 20148/4/2014Endoscopic Treatment of Salivary Glands Affected by Sjögren's SyndromeEndoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome; A Randomised Controlled Pilot StudySjögren's SyndromeProcedure: Sialoendoscopy;Drug: saline;Drug: hydrocortisoneDerk Jan JagerNULLActive, not recruiting18 Years70 YearsAll50N/ANetherlands
3NCT01357447
(ClinicalTrials.gov)
May 201118/5/2011Pulmozyme for Sjogren's Associated CoughA Double-blind, Placebo-controlled Cross-over Trial of Pulmozyme for Sjogren's Associated CoughSjogren's Syndrome;CoughDrug: Dornase alfa;Drug: SalineUConn HealthNULLWithdrawn18 YearsN/AAll0Phase 1United States
4EUCTR2007-001708-19-FR
(EUCTR)
23/08/200706/08/2007A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, phase III trial.A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, phase III trial. treatment on bilateral moderate dry eye syndrome due to Sjögren's syndrome or diagnosed as a primary syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10013774;Term: Dry eye
Product Name: SVS20
Product Code: SVS20
INN or Proposed INN: sodium hyaluronate
Trade Name: Lacryvisc
INN or Proposed INN: carbomer 974P
Product Name: SALINE
INN or Proposed INN: sodium chloride
TRB CHEMEDICA INTERNATIONAL SANULLNot RecruitingFemale: yes
Male: yes
300Phase 3France;United Kingdom